β-Amyloid 1-42 (Commercial assay)
A 42-amino acid peptide fragment of amyloid precursor protein, serving as a core biomarker for amyloid pathology in neurodegenerative diseases.
Key features and values
- accumulation.
- Reflects amyloid pathology, providing insights into disease progression.
- Validated for use in human biofluids, ensuring reliable and reproducible measurements.
- Non-invasive tool for assessing amyloid accumulation, suitable for routine sampling.
- Reduced β-Amyloid (1-42) levels correlate with increased amyloid deposition in conditions such as Alzheimer’s disease.
- Useful for monitoring therapeutic response, with changes in β-Amyloid (1-42) levels reflecting the efficacy of anti-amyloid treatments.
- Facilitates research and development of targeted therapies by providing insights into amyloid pathology mechanisms.
Description
The β-Amyloid (1-42) biomarker assay is designed to quantify the 42-amino acid form of amyloid beta in cerebrospinal fluid or plasma, serving as a specific indicator of amyloid plaque accumulation. β-Amyloid (1-42) is a peptide fragment derived from amyloid precursor protein, and its reduced levels in biofluids reflect increased deposition in brain tissue. By measuring β-Amyloid (1-42), the assay provides a direct assessment of amyloid pathology.
This assay has been validated for use in human biofluids, demonstrating its reliability and reproducibility in various clinical and research settings. Reduced β-Amyloid (1-42) levels have been associated with increased amyloid deposition in conditions such as Alzheimer’s disease. The non-invasive nature of the test makes it suitable for routine monitoring of amyloid accumulation and the effectiveness of anti-amyloid therapies.
In addition to its clinical applications, the β-Amyloid (1-42) assay serves as a valuable tool in research, facilitating the study of amyloid pathology mechanisms and the development of targeted treatments aimed at modulating amyloid accumulation processes.
